ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

5.66

-0.17 (-2.91%)

Jul 30, 2026, 10:25 AM EDT - Market open

ARS Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-197.98	-171.3	8	-54.37	-34.68	-20.24
Depreciation & Amortization	1.48	1.37	0.08	0.07	0.03	0.21
Stock-Based Compensation	24.22	22.1	14.53	9.24	5.84	2.83
Other Adjustments	-4.55	-3.03	-7.25	-6.85	1.48	-0
Change in Receivables	-16.92	-17.21	-8.18	-	-	-
Changes in Inventories	-13.83	-21.99	-5.95	-	-	-
Changes in Accounts Payable	25.03	18.88	16.41	-2.78	-10.29	0.97
Changes in Unearned Revenue	-0.2	-0.35	2.09	-3.14	-1.32	-2.51
Changes in Other Operating Activities	4.92	0.66	-6.19	-1.45	-1.15	1.18
Operating Cash Flow	-175.07	-170.87	13.55	-59.27	-40.08	-17.56
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-0.2	-0.34	-0.56	-0.18	-0.2	-0.06
Purchases of Intangible Assets	-	-7.86	-7.5	-	-	-
Purchases of Investments	-222.4	-242.03	-356.04	-272.01	-	-
Proceeds from Sale of Investments	286	307	258	185	-	-
Investing Cash Flow	55.5	56.77	-106.1	-87.18	-0.2	-0.06

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Long-Term Debt Issued	-	96.26	-	-	-	-
Long-Term Debt Repaid	-	-	-	-	-8.68	-1.82
Net Long-Term Debt Issued (Repaid)	-	96.26	-	-	-8.68	-1.82
Issuance of Common Stock	5.02	5.68	3.02	6.9	0.57	0.17
Net Common Stock Issued (Repurchased)	5.02	5.68	3.02	6.9	0.57	0.17
Issuance of Preferred Stock	-	-	-	-	-	54.81
Net Preferred Stock Issued (Repurchased)	-	-	-	-	-	54.81
Other Financing Activities	0.1	2.66	69.38	-	198.84	-
Financing Cash Flow	102.9	104.6	72.4	6.9	190.73	53.16

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash Flow	-15.54	-9.5	-20.15	-139.55	150.46	35.54

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-175.27	-171.21	12.99	-59.44	-40.28	-17.62
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-177.06%	-203.14%	14.57%	-198137.00%	-3060.56%	-319.94%
Free Cash Flow Per Share	-1.77	-1.74	0.13	-0.62	-1.01	-0.61
Levered Free Cash Flow	-180.77	-76.81	13.88	-61.83	-56.28	-22.26
Unlevered Free Cash Flow	-185.21	-181.14	2.91	-74.98	-48.44	-19.65

SEC Filings: 10-K · 10-Q